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Abstract
Background: External and internal factors are increasingly encouraging research funding bodies
to demonstrate the outcomes of their research. Traditional methods of assessing research are still
important, but can be merged into broader multi-dimensional categorisations of research benefits.
The onus has hitherto been on public sector funding bodies, but in the UK the role of medical
charities in funding research is particularly important and the Arthritis Research Campaign, the
leading medical charity in its field in the UK, commissioned a study to identify the outcomes from
research that it funds. This article describes the methods to be used.
Methods: A case study approach will enable narratives to be told, illuminating how research
funded in the early 1990s was (or was not) translated into practice. Each study will be organised
using a common structure, which, with careful selection of cases, should enable cross-case analysis
to illustrate the strengths of different modes and categories of research. Three main
interdependent methods will be used: documentary and literature review; semi-structured
interviews; and bibliometric analysis. The evaluative framework for organising the studies was
previously used for assessing the benefits from health services research. Here, it has been
specifically amended for a medical charity that funds a wide range of research and is concerned to
develop the careers of researchers. It was further refined in three pilot studies. The framework has
two main elements. First, a multi-dimensional categorisation of benefits going from the knowledge
produced in peer reviewed journal articles through to the health and potential economic gain. The
second element is a logic model, which, with various stages, should provide a way of organising the
studies. The stock of knowledge is important: much research, especially basic, will feed into it and
influence further research rather than directly lead to health gains. The cross-case analysis will look
for factors associated with outcomes.
Conclusions: The pilots confirmed the applicability of the methods for a full study which should
assist the Arthritis Research Campaign to demonstrate the outcomes from its funding, and provide
it with evidence to inform its own policies.
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The growing concern for the benefits from health research 
to be studied
Health research funding bodies are under increasing pres-
sure to demonstrate the outcomes, or benefits, of the
research that they fund [1-6]. Traditional peer review of
research focussed on the outputs in terms of journal arti-
cles, the training of future researchers and the develop-
ment of careers. These are still seen as important, but in
some analyses they have been merged into broader multi-
dimensional categorisations of the benefits from health
research [7,8].
The onus hitherto has been on public sector funding bod-
ies. There is a general recognition in the UK, however, of
the importance of the role of the medical charities: they
fund approximately one third of UK medical research – a
level 'unparalleled elsewhere in the world and nor is it
found in other areas of science' [9]. Therefore, in an era of
accountability, public involvement in research issues and
growing competition for contributions, some medical
charities see the virtue in being able to demonstrate the
outcomes of the research they fund. Not all the pressures,
however, are external and some funding bodies, including
the Wellcome Trust, which is an endowment and not col-
lection-based charity, are being pro-active in their
attempts to identify and track the outcomes of the
research they fund. One factor relevant for both public
sector and charity funding bodies is the recognition that
assessing the benefits from their research may assist in
identifying research strategies most likely to produce ben-
efits [2,7,10,11]. Concerns such as those above led a UK
medical charity, the Arthritis Research Campaign (ARC),
to approach RAND Europe with the idea of conducting an
assessment of the long-term outcomes from research that
they have funded.
The purpose of this paper is to set out the aims of the
study and the methods being adopted. In particular, it will
show how an existing generic approach to the assessment
of benefits from health research [7,12] has been adapted
to meet the needs of this specific study. After providing the
background to the study, the paper describes the methods
to be adopted. These were initially agreed after a consult-
ative phase in which the evaluative framework was refined
on the basis of interviews with six key actors who have
played various roles within ARC and advice from ARC's
Development Committee, which acts as the steering
group for this project. They were then confirmed follow-
ing a pilot stage in which three case studies were con-
ducted; some examples from the pilot studies, which
endorsed the feasibility of the proposed approach, will be
given to illustrate the account of the methods.
The increasing attention on musculoskeletal conditions 
and the role of the Arthritis Research Campaign (ARC)
Attention is being drawn to the increasing scale of the bur-
den of musculoskeletal conditions, and the associated
costs, in various ways including through the establish-
ment of the Bone and Joint Decade 2000–2010 and the
recent collaborative report with the World Health Organ-
ization (WHO) [13]. At the same time, there is a realisa-
tion that the benefits of research in this area are
sometimes less immediately apparent than in some other
fields. For example, two classic studies of the economic
benefits from biomedical research [14,15] both high-
lighted arthritis as an area where research and higher med-
ical care expenditure may have comparatively little impact
on mortality. Furthermore, one recent attempt to put a
monetary value on the benefits from health research in
Australia [16] adapted a method developed in the USA
[17] and again demonstrates the difficulties of undertak-
ing such analysis in the musculoskeletal field. These
observations might suggest that a more careful and wide-
reaching assessment of benefits from research is particu-
larly needed in the field of arthritis.
ARC is the leading medical charity in this field in the UK
and one of the largest collection-based medical charities
in the UK. The Research Outputs Database (ROD) records
the funding acknowledgements on all UK biomedical
papers contained on the citations indices of the Institute
for Scientific Information [18]. Analysis conducted on
ROD reveals ARC to be, 'in a dominant position within
the UK in the arthritis subfield' [19]. ARC's funding is
associated with more arthritis publications than that from
either the Medical Research Council (MRC) or the Well-
come Trust. It spent almost £22 million in the year 2001–
2002; its major aim 'is to support the highest quality
research into the cause, cure and treatment of arthritis and
musculoskeletal diseases' [20]. It adopts a variety of fund-
ing modes for a range of types of research including its
support of two research centres. The preliminary inter-
views, described above, highlighted the importance of the
work by Marc Feldmann and Sir Ravinder Maini at one of
these, the Kennedy Institute of Rheumatology in London,
in developing anti-Tumour Necrosis Factor (anti-TNF)
therapy as an effective treatment for rheumatoid arthritis
and other autoimmune diseases. The pair won the 2003
Albert Lasker Award for Clinical Medical Research for this
discovery.
Objectives of the evaluation/research questions
Within the general climate of an increased emphasis on
the outcomes from research, four main objectives were
specified for the particular study described in this article:
• Review and document outcomes for ARC research grantsPage 2 of 11
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modes of research funding
• Identify factors associated with translation of research,
and attempt to develop 'early indicators' of likely success-
ful translation
• Identify 'good news stories' and vignettes of the research
process for use by ARC in public engagement and fund
raising activities.
Methods
Rationale for using a case study approach
Traditional methods of peer review have long been
favoured by medical research funding bodies for evaluat-
ing research, but bibliometric methods have had a varia-
ble history. An early move by the National Institutes of
Health (NIH) to establish a publications' database was
cancelled by the 1980s 'as too expensive for the manage-
ment information it produced' [21]. The MRC in the UK
reviewed the possibility of making greater use of biblio-
metric measures to inform per review of major long term
programmes, but the steering group established to oversee
the review concluded that, 'bibliometric analysis would
not add sufficient value to peer review to be worthwhile
routinely and should not be introduced into MRC proce-
dures' [22]. Nevertheless, there are circumstances where
bibliometric analysis can provide research funding bodies
with useful information [19] and, as discussed below,
they can be incorporated into broader case studies. On its
own, however, it is unlikely to provide much information
about the longer-term outcomes from research funding.
The Economic and Social Research Council (ESRC) in the
UK commissioned a project to identify the impact of their
research on non-academic audiences. It involved tracing
the activity of the participating researchers after their
projects ended and mapping the networks of researchers
and relevant non-academic users and potential beneficiar-
ies [23]. The study concluded that the preferable way to
determine and assess the existence of impacts of socio-
economic research on non-academic audiences 'is
through detailed, project-by-project qualitative analysis'
[23]. Such an approach probably entails adopting a case
study approach, and there is a long history of applying the
case study approach to examine the utilisation of research
[24]. Indeed, where the emphasis is on demonstrating the
outcomes from health research, a case study approach has
mainly been used [7,25] and been recommended for use
in future studies [4,26,27].
Case studies will enable narratives or stories to be told to
illuminate how the research funded in the early 1990s was
translated (or not) into practice; each case, therefore,
could potentially provide an illustrative example of the
outcomes from ARC research. Furthermore, the planned
16 case studies will be based on a variety of modes of ARC
research funding and types of research. They will also be
organised using a common structure. This should enable
cross-case study analysis to demonstrate (via illustrative
case studies) the strengths and weaknesses of different
modes of funding and categories of research. It should
also facilitate the identification of factors associated with
the translation of research, perhaps through various
phases, into policies, products, and clinical practice that
produce a health gain.
The evaluation framework described below was devel-
oped in a way that incorporates previous experience and
knowledge on these issues [7,12,24,26,28]. This should
ensure that questions are asked about a range of factors
that previous experience suggests are likely to be related to
the translation of research. Additionally, because the eval-
uation framework includes a multi-dimensional categori-
sation of benefits from research, the full range of outputs
and outcomes relevant to different types of research, and
modes of funding, will be looked for in the studies. The
case studies will, in part, be conducted to see if they pro-
duce evidence consistent with existing hypotheses about
factors linked to the translation of research and the role of
different modes of research funding and types of research.
But they will also be exploratory and should allow the
generation of new hypotheses, particularly ones specifi-
cally relevant for research funding from a medical charity.
Timescale
In deciding the time window to use for selecting case stud-
ies, a compromise usually has to be made between the
quality of records/likely ability of researchers to recall
their activities and the selection of grants whose outputs
have had sufficiently long to develop [29]. The latter point
was important in this study because the aim was to move
beyond considering traditional outputs and also examine
outcomes such as health gains. ARC instituted a new com-
puterised database during the early 1990s and all their
grants awarded since 1990 are held on this database. Prior
to this, only paper records of unknown completeness were
available. As an appropriate compromise between the var-
ious factors, we therefore decided to select grants that were
awarded between 1990 and 1994.
Selection of cases
Within a case study approach it is unlikely that the selec-
tion of cases will follow a straight-forward sampling logic
in which those selected are assumed to be representative
of a larger group [30]. Nevertheless, in adopting a multi-
case approach the project aims to ensure not only that the
benefits from the full range of modes of funding and types
of research can be illustrated, but also that there is scope
for some cross-case analysis. The selection of cases will,Page 3 of 11
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four modes of funding will be included: institute grant,
programme grant, project grant and fellowships. ARC-
funded researchers will also be divided into three groups
on the basis of their qualifications: basic researchers, clin-
ical researchers, and Allied Health Professionals (AHP)
such as physiotherapists. In their classic case study analy-
sis of research utilisation, Yin and Moore [24] went to
considerable lengths to ensure that they were including
only studies where it was thought there had been utilisa-
tion. We do not propose to go that far, but, given that the
idea is to illuminate the outcomes, it is considered desira-
ble to concentrate on studies where it is thought there is a
reasonable chance that there will be something to show.
When examining the outcomes of research, even a strati-
fied sampling approach is not thought to be sufficient
because most impact usually comes from a small number
of studies [23].
As a first step, we shall identify all publications in the rel-
evant period from the principal investigators awarded
ARC funds. Then, the researchers will be classified accord-
ing to the journal impact factors (see below) of the jour-
nals in which their articles appear. The aim will be to draw
up shortlists of possible researchers to include in the
study: those in the top decile and those the middle of the
range, with the final selection made on the basis of advice
from ARC's Development Committee.
Organisation of data collection
For case studies it is appropriate to use multiple sources of
evidence converging on the same issues [4] and adopt a
process of triangulation [27,30]. Three main interdepend-
ent methods will be used: documentary and literature
review; semi-structured interviews with key informants;
and bibliometric analysis. They will be applied in a par-
tially overlapping way.
Documentary and literature review
We will read key project documents including the original
research grant proposals, referees' reports and end of
project reports. On the basis of the end of year reports
from researchers, and the interviews (see below), we will
also identify and read the core publications attributed to
the research grant and any subsequent publications such
as key citing papers, relevant clinical guidelines etc.
Semi-structured interviews with key informants
There will be about three interviews per case study. They
will be based on a semi-structured interview schedule
informed by the evaluation framework described below.
They will, therefore, explore the origins of the research
and the primary outputs such as the publications. In this
way the initial list of publications identified as being
related to the project will be refined. Furthermore, there
will be a full exploration not only of the contribution to
research training and career development, but also of any
translation of the research findings into product develop-
ment, policy and practice. In each case study the initial
interviews will be with members of the relevant research
team. Then snowballing techniques will be used to iden-
tify the people who might be able to provide most infor-
mation about how the research has influenced
subsequent research or been translated into product
development, policy and practice.
Bibliometric analysis
Bibliometric approaches can play a useful role in the anal-
ysis of the research funded by specific biomedical
research-funding bodies [19,31]. In the current analysis,
the list of research papers published as a result of the
project will first be refined as described above. Following
that, bibliometric analysis will be conducted to record var-
ious matters including: the full funding acknowledge-
ments; number of authors; citation counts; and
comparison of number of citations with the journal
impact factor of the publishing journals. This analysis will
be conducted by a further part of the research team: those
responsible for maintaining the ROD described above.
Clearance and validation
In every case a draft copy of the case study report will be
sent to the principal investigator for comment. Such a step
is an important part of the validation process and not just
a matter of professional courtesy [24].
Evaluation framework for ARC case studies
There are two elements in the evaluation framework
adopted to organise the case studies being conducted in
the assessment of the outcomes from ARC-funded
research. Building on the framework developed by Buxton
and Hanney [7,12], the two elements consist of a multi-
dimensional categorisation of benefits from health
research, and a model of how best to assess them. A logic
model such as this helps facilitate assessment rather than
pretending to be a precise model of how research utilisa-
tion occurs. The framework has been developed in various
ways to meet the particular circumstances of ARC-funded
research, which is often basic and investigator-led.
There are many steps involved in assessing outcomes from
research. One of the key advantages in taking a detailed
approach, such as that described below, is that it enables
the issue of the counter-factual to be addressed. In other
words, what would the world have looked like without
the specific research being examined?Page 4 of 11
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The multi-dimensional category of payback provides the
evaluation criteria for the outputs and outcomes from
ARC funding. The 5 main categories are:
a) Knowledge production
b) Research targeting, capacity building and absorption
c) Informing policy and product development
d) Health benefits
e) Broader economic benefits.
Each can be considered in turn, with various sub-catego-
ries explored and possible measures described.
Knowledge production
The knowledge produced by research is the first output
and is contained in various publications and patent appli-
cations. Any type of publication can be considered, but it
is generally thought that peer reviewed articles are the
most important and, at least for biomedical research in
industrialised countries, it is thought reasonable to
assume that the overall output of research publications is
fairly represented by peer-reviewed papers in interna-
tional journals [19]. In addition to counting the number
of publications, their quality and their impact can be
assessed in various ways. The quality of knowledge pro-
duction has traditionally been assessed by peer review,
but various other methods can be applied. Papers that are
accompanied by an editorial are often seen as being of
particular significance. For those studies that are included
in a systematic review there are now formal quality assess-
ment techniques [32], as there are for reviews appearing in
an overview [28].
Citation analysis can be applied to assess the impact the
specific article is having within the research community
[33,34]. Previous experience suggests that knowledge pro-
duction will be particularly important for basic research,
and certainly, on average, papers in basic research journals
tend to be cited more frequently than ones in clinical jour-
nals [19,35].
A journal's 'impact factor' is based on the average number
of times an article in the journal is cited; it can provide a
short-hand version of citation analysis by giving some
indication of the importance of the journal in which an
article appears. The use of impact factors in analysis of
biomedical research has been criticised [36] but, provided
care is taken [37], it has been shown to be of some value
[19].
Particularly when considering research that might be
aimed at potential users outside the research community,
it is often desirable to use a range of publication outlets
including those journals with the highest readership
among the groups at whom the research is targeted. In
some fields these might well be journals that do not have
an impact factor but are, nevertheless, significant as vehi-
cles for dissemination of the knowledge produced [38-
40].
Research targeting, capacity building and absorption
The better targeting of future research is frequently a key
benefit from research, especially from research that is
more basic and/or methodologically oriented. An indica-
tion of this comes from citation analysis. The enhanced
targeting can be of the research conducted both by others
and by the original researcher(s). Where follow-on
research, especially by members of the original research
team, is clearly associated with the original research it can
be useful to obtain information on the source and
amount of such funding [39]. As is developed in the par-
agraph below, one of the key roles of a medical charity can
be to fund research in its field that will help to open up
questions/issues that will then attract further funding
from the general research funders such as the MRC and
the Wellcome Trust.
Research training can be provided both as a result of the
employment of staff on research projects and pro-
grammes, and through explicit funding for research train-
ing and career development [1]. One measure of research
training, which may appear crude but has nevertheless
been used in previous studies, is the number and level of
higher or research degrees resulting, either totally or in
part, from the research funding [1,14,39,41]. The career
development of arthritis researchers goes much wider
than specific training and is of considerable importance to
ARC which aims to ensure that the pool of researchers in
this field is a strong as possible. The reasoning is that this,
in turn, should help ensure that arthritis as a topic is able
to gain an appropriate share of the research funding avail-
able from general medical research funders. Some of
ARC's funding schemes aim explicitly to provide career
development, and for other researchers the receipt of a
project grant from ARC can be important in advancing
their career in research. Interviews can address this. Fur-
thermore, they may also enable us to consider how far
career development based on ARC funding helps propel
some researchers into positions within the health-care sys-
tem where they can play a role in ensuring that the later
stages of translating research findings into outcomes are
achieved.Page 5 of 11
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Research can be used to inform policymaking in a wide
range of circumstances and the key issue is that policy-
making involves those in positions of authority making
choices that have a special status within the group to
which they apply [27]. Policymaking is interpreted very
broadly here and refers not just to national policies of the
government, but also includes: policies made by manag-
ers at many levels within a health service; policies agreed
at national or local level by groups of health-care practi-
tioners in the form of clinical or local guidelines; policies
developed by those responsible for training/education/
inspection in various forms including training packages,
curricula and audit and evaluative criteria [3]; and policies
about media campaigns run by health-care providers.
Basic research is less likely than that from clinical
researchers or AHP to be used to inform policy. Various
methods have been proposed for analysing the impact of
research on health policymaking, including documentary
review and interviews [26,27].
The position of systematic reviews is a little complex. They
are themselves a form of research, but inclusion of a study
in a systematic review is a form of secondary output and
might lead on to further use.
At a similar level, although involving very different proc-
esses, research can also be used to inform product devel-
opment [38]. Informing policies and product
development are conceptually similar in that there gener-
ally has to be some subsequent adoption of the policy, or
product, before the health and economic benefits can
accrue [7].
Health benefits
Benefits in terms of health gains might be viewed as the
'real' payback or outcomes from health research. Greater
effectiveness of health-care resulting from research-
informed drugs or procedures should lead to increased
health. Various measures of health gain exist, but for
arthritis the emphasis, in most cases, is likely to be on
those that assess reduction in pain or disability, and
increase in mobility. While the benefits from arthritis
research will not generally be measured in terms of life
years gained, in some circumstances they might be cap-
tured by using Quality Adjusted Life Years (QALYs). This
is often seen, in countries such as the UK, as a more appro-
priate approach than using Disability Adjusted Life Years
(DALYs) [42]. There have been recent attempts to put a
monetary valuation on the reduction in mortality and
morbidity as a result of health research [16,43], but that is
not being proposed for this study. At an overall level, it is
possible that figures for the potential population who
could benefit from the new drug or procedure could be
identified, along with information about the level of ben-
efit that individual patients might receive. If knowledge
about adoption levels was then also taken into considera-
tion it might be possible to indicate overall levels of
benefit.
This category of benefits can be thought of as going wider
than health gain, and some aspects can be seen as benefits
to the health sector more generally. Cost savings in the
provision of health-care may result from research-
informed changes in the organisation of services or in the
particular therapies delivered. It might be necessary to
consider various issues here. These include whether
potential savings have in practice been realised – either as
cash savings or as the release of resources for other valua-
ble uses [44]. Furthermore, it would be important to
check whether costs are not simply being transferred else-
where. Improvements could also arise in the process of
health-care delivery and these could be measured by tech-
niques such as patient satisfaction surveys [7].
Broader economic benefits
A range of benefits can accrue to the national economy
from the commercial exploitation of research. These can
take the form of employment and profits resulting from
the manufacture and sale of drugs and devices [45]. The
national economy could also benefit from exports and/or
import substitution [46,47].
Whilst there is a danger of double counting, it is probably
also important to adopt a human capital approach and
focus on the value of production gained from having a
healthy workforce. This can be measured by examining
the reduction in days off work. Typically, in a human cap-
ital approach, potential future earnings are calculated for
people who, as a result of advances in medical research,
can continue to contribute to national production
[14,15,48]. Those who use it, however, share the concerns
that such an approach to assessing the benefits from
research could have equity implications in that it would
seem to favour research relevant for those of working age.
This concern might be relevant here, in that many who
suffer most from arthritis are retired, but reducing the days
off work caused, for example, by low back pain, could be
important. The economic burden of low back pain has
been identified [49] and the potential role of research in
reducing it was recently highlighted in a wide-ranging dis-
cussion of the benefits from medical research in the USA
[50].
Model for assessing the outputs and outcomes
The second element of the evaluation framework is the
logic model. Its various stages are shown on Figure 1 and
provide a way of organising the case studies. At least seven
stages and two interfaces are identified and although they
are presented in a linear form, the reality is much morePage 6 of 11
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[7,12].
Stage 0: Topic/issue identification
Interface A: Project specification and selection
Stage 1: Inputs to research
Stage 2: Research processes
Stage 3: Primary outputs from research
Interface B: Dissemination
Stage 4: Secondary outputs – policymaking and product
development
Stage 5: Adoption by practitioners and public
Stage 6: Final outcomes
While it is not possible totally to tie the categories of ben-
efits to certain stages of the model, it is possible to identify
broad correlations: categories a) and b) (knowledge and
research benefits respectively) are together considered to
be the primary outputs from research; category c)
(informing policy and product development) relates to
the secondary outputs; and categories d) and e) (health
and broader economic benefits respectively) are the final
outcomes. This approach can be incorporated into the
analysis of each stage in turn as is set out below, where a
few examples, drawn from the pilot studies, are used to
illustrate how the framework seemed to be working in
practice but could be refined in certain ways.
Stage 0: Topic/issue identification
The topic or issue identification stage covers the genera-
tion of the original ideas for the research. Its nature can
vary considerably depending on whether the main driving
force is internally generated by the researcher, or exter-
nally generated [27]. Most ARC funding falls into the
former category: for many researchers the topics will be
curiosity-driven and based on examination of the existing
stock or pool of knowledge and opinions about where
gaps, and/or opportunities, exist and further research
could advance understanding. Such factors will also
inform more clinical and AHP researchers, but here con-
sideration of clinical needs could also be a factor and
might be based on personal experience of treating
Model for Organising the Assessment of the Outcomes of Health ResearchFigure 1
Model for Organising the Assessment of the Outcomes of Health Research. Sources: Adapted from previous ver-
sions of the Buxton/Hanney model for assessing the payback from health research [12,27].
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pal investigator in one of the case studies. Where research
topics are externally generated, the identification of the
issue comes from a process of needs assessment that could
involve analysis either just within the scientific commu-
nity or more widely. In the latter case, many groups could
be involved. These include not only members of the wider
research community and representatives of research fund-
ing bodies, but also potential users and beneficiaries of
the research drawn from some combination of the wider
political, professional, industrial and societal
environment.
Interface A: Project specification and selection
The nature of the activities at Interface A will vary depend-
ing on the type of issue identification. Where the topics
are externally generated, there are potential difficulties in
ensuring both that the research community is actively
engaged with the priorities that have been identified and
that the project specification meets the needs as identified
[27]. Where the issues are internally generated, the inter-
face involves traditional processes of the researcher devel-
oping a detailed proposal and submitting it for peer
review. Most of the issues are internal to the scientific
world, but there is still a key interface between individual
researchers and ARC as the research-funding body. Docu-
mentary analysis of ARC files provided information in the
pilots that sometimes highlighted issues about how far
the proposal was subject to changes as a result of the
review process. It also proved useful, however, to supple-
ment this with questions in the interviews.
Stage 1: Inputs to research
It can be important to consider not only the financial
inputs, including any beyond the specific ARC funding,
but also the experience of the research team and the
knowledge base on which they built. Part of the idea
behind examining any other funding brought in to sup-
port ARC research is again to see how far ARC funding is
helping to facilitate the funding of arthritis research by
general funders of health research: is ARC funding studies
that produce findings that others believe are worth further
investigation? The pilot studies confirmed that the com-
plexities of identifying the exact funding streams behind
any piece of research were best addressed by using a case
study approach involving initial documentary review and
following up issues in interviews. The pilots involved a
case where other contributory funding contributed to
what was clearly an ARC project, and therefore little
attempt was made to portion out credit for outcomes to
any funder other than ARC. In another case, however, the
research was part of a stream of ARC-funded work and an
effort was made to try to draw boundaries around what
would be appropriate to include in the case study.
Stage 2: Research processes
Consideration can be given to how appropriate the pro-
posed methods for a study turned out to be, and whether
any difficulties were encountered. In some cases it could
be relevant to explore how far potential users were
involved at this stage. It is possible that difficulties identi-
fied at this stage could explain later problems with trans-
lation or uptake of the research findings.
Stage 3: Primary outputs from research
Knowledge production, as represented by the various
types of publications, is a major primary output from the
research. Various ways of measuring this were discussed
above. The pilots also showed that the interviews used to
refine the lists of publications from the specific funding in
question, could also sometimes help to identify where
non-conventional sources were being used as outlets for
publications. Most of the primary outputs will feed into
the stock of knowledge.
The research benefits in terms of targeting future research
represent either feedbacks to further research conducted
by team members, or findings that feed into the stock of
knowledge and help target future research of others. An
example from one pilot study showed not only how the
principal investigator used her project to inform her own
further work, but was also able to contribute to a much
larger collaborative project. Interviews in another study
showed that the research had informed considerable fur-
ther work in industry, but as yet this had not led to any
product development. Under the framework being used,
it is possible to give that ARC-funded work considerable
credit for informing the further research, but record its
limited impact at the subsequent stages.
Capacity building can also be seen as a primary output.
Accounts were given, in pilot study interviews, of the
research training and higher degrees that resulted from the
research.
Interface B: Dissemination
Dissemination is usually seen as being somewhat more
active than the mere production of academic publications
containing the knowledge. There are, however, clear over-
laps between some activities. Sometimes it is possible to
record not just dissemination activities but also the suc-
cessful transfer of research findings to potential users in
the political, industrial, professional environment and
wider society. Previous analyses of how to increase the
implementation of research findings [28] will help inform
the issues being examined in the case studies at the dis-
semination and later stages. Presentations to potential
academic and user groups, and media activities, are major
ways of disseminating findings, as are the production of
brief summaries of findings targeted at specific userPage 8 of 11
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focused on the way some researchers conduct study days,
or training, based on the approach developed by their
research and these can be highly effective dissemination
mechanisms [51]. The pilots provided an example of the
importance of this and, indeed, of the role of individual
researchers in networking and disseminating
information.
Stage 4: Secondary outputs–policymaking and product development
As noted above, policymaking and product development
activities can result in a wide range of secondary outputs,
and various methods are needed to identify research-
informed policies. In one case study, a review of a data-
base revealed that one project had been cited in a clinical
guideline unbeknown to the research team, whereas in
another pilot it took interviews to identify that the
research was informing local guidelines and care path-
ways. The use of the research in systematic reviews was
also revealed in various ways in the pilot studies. Where
the research seems to have resulted in secondary outputs
it is useful to explore the factors that have led to this.
In relation to product development, if research findings
are incorporated into the process of developing a product,
for example a new drug for arthritis, this can be seen as an
important secondary output. In the preliminary set of
interviews, most people referred to how ARC-funded
research had played a key role in the production of anti-
TNF therapy for arthritis. In a pilot study, interviews
revealed the extent to which industry's attempts to use one
stream of research for product development had not, so
far, been successful.
Stage 5: Adoption by practitioners and public
For the research findings incorporated into secondary out-
puts to result in final outcomes there usually has to be
some behavioural change by practitioners, and/or the
public. This may involve take-up of new drugs or proce-
dures as set out in a secondary output such as a guideline
from the National Institute for Clinical Excellence (NICE).
Sometimes the adoption comes as a direct result of the
primary outputs, as when clinicians – often at the cutting
edge – decide to implement research findings even prior
to the development of clinical guidelines. Either way, it is
important to try to establish the adoption or take-up rates
and to explore how far the behavioural change can be
attributed to the specific research findings, as opposed to
other factors such as a more general change in climate of
opinion in relation to, for example, the importance of
exercise. In one pilot study where interventions based on
research filtered into practice, a series of interviews was
used to attempt to identify both the precise role of the spe-
cific ARC-funded project and possible levels of uptake.
The role of the public in responding to informed advice –
often research-based – is seen as increasingly important,
especially in a field such as arthritis [52]. Various factors
can be explored here. These include the extent to which
patient behaviour might change as a result of interactions
with health-care providers who promote research-based
messages, and how far the public might respond directly
to publicity about research findings when they are used,
for example, in media campaigns encouraging participa-
tion in preventative activities [28].
Stage 6: Final outcomes
The final outcomes are the health and broader economic
benefits identified in categories d) and e) above. These are
increasingly seen as being the ultimate goal of health
research funding, but their precise estimate in practice
often remains difficult [5-7]. In one pilot study, it was pos-
sible to produce audit figures from one area where there is
known to have been local implementation of the research
findings.
Planned analysis and synthesis
Each of the 16 cases will be written up as a narrative
organised according to a common structure based on the
various stages of the logic model. Each study should
potentially, therefore, provide illumination as to the proc-
esses that could lead to outcomes and illustrations of such
outcomes. In addition, the common structure of each case
should facilitate some cross-case analysis that will not
only look for common factors associated with research
that has led to outcomes, but also see how far such out-
comes are associated with different modes of funding and
types of research. Some of this analysis should be based
on the previous findings that are embedded into the eval-
uation framework: for example, basic research might be
expected to produce a reasonable number of knowledge
outputs but be less likely than clinical or AHP research to
inform policies. Some other aspects of the analysis, how-
ever, are likely to be exploratory: detailed analysis of fac-
tors related to the role of medical charity research in
contributing to outcomes appear, as yet, not to be well
established.
Conclusions
This paper sets out the aims and methods to be adopted
in an innovative study to review the outcomes of the
research funded by the Arthritis Research Campaign, one
of the leading medical charities in the UK. At a time of
growing emphasis on both accountability and evidence-
based policy making, it is important for research-funding
bodies to be able to show the results of their funding and
base their policies on analyses of the processes involved in
producing outcomes [53]. Based on the results of the
piloting, a decision was made to go ahead with the full
study.Page 9 of 11
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ationalise such analysis on a regular, and therefore less
resource intensive, manner. It is hoped that the study will
also shed light on these practical considerations, and do
so in a way that will enable a system to be developed that
meets the specific needs of the particular research funding
body [4], in this case ARC.
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